Anja Haltner, MSc
Associate Director, Biostatistics, Value & Evidence Services
Expertise:
Anja brings over 10 years of academic and industry experience in applied statistical analyses. Anja’s research focuses on population-adjusted indirect treatment comparisons including matching-adjusted indirect comparisons, simulated treatment comparisons, and propensity score matching and reweighting.
Articles by Anja Haltner, MSc
Evaluating PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and quality of life. Historically, patients with mCRPC had limited therapeutic options, and despite advancements in therapeutic innovation, the five-year relative survival rate for metastatic prostate cancer remains low (~34%). Encouragingly, multiple randomized clinical trials have recently demonstrated promising responses to novel poly (ADP-ribose) polymerase (PARP) inhibitors – such as talazoparib, niraparib and olaparib, in combination with androgen receptor pathway inhibitors – and represent a new class of therapies for first-line treatment of mCRPC. However, there has been no direct comparative trial conducted between these combinations of PARP and androgen receptor pathway inhibitors. When such trial data […]
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have been demonstrated for many 1L mCRPC treatments, including novel agents such as talazoparib plus enzalutamide. However, due to the lack of direct comparisons, it is unclear how new treatments compare to many of those already used in clinical practice, creating challenges when choosing which therapeutic option to recommend to patients. To help bridge this gap, Elena Castro, MD; the team at Pfizer Inc. (Alexander Niyazov and Jonathan Nazari); and the Value & Evidence team […]
EVERSANA’s High-Quality HEOR Methods Recognized in Published Independent Review
A recent independent review conducted by Serret-Larmande and colleagues, featured in the Journal of Clinical Epidemiology, meticulously evaluated population-adjusted indirect comparisons published from 2010-2022. The analysis focused on assessing the reporting quality of methods and results across identified articles. The review, which scrutinized 133 articles, revealed a prevalent issue of unclear, inconsistent, or even absent reporting. The authors highlighted this observation, emphasizing the need for improvement in reporting standards. Despite these challenges, the discussion section of the review acknowledged two studies that demonstrated noteworthy methodology and reporting completeness. Notably, one of these two studies was an MAIC published in 2021 by EVERSANA. It is worth noting that this particular publication […]